Client News

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Repronovo appoints Mark Altmeyer as chairman of the board

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract

AFYREN obtains ISO 9001 certification, a globally acknowledged standard of rigor and performance, for its AFYREN NEOXY plant

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer